Skip to content
Business
Link copied to clipboard

Pfizer completes Baxter vaccine acquisition

Drugmaker Pfizer Inc. said Monday it completed the acquisition of Baxter International Inc.'s portfolio of marketed vaccines. Pfizer also acquired a portion of Baxter's facility in Orth, Austria, where some vaccines are manufactured. The two vaccines are called NeisVac-C and FSME-IMMUN/TicoVac.

Drugmaker Pfizer Inc. said Monday it completed the acquisition of Baxter International Inc.'s portfolio of marketed vaccines.

Pfizer also acquired a portion of Baxter's facility in Orth, Austria, where some vaccines are manufactured. The two vaccines are called NeisVac-C and FSME-IMMUN/TicoVac.

NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococci (MenC).

FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis, an infection of the brain, which is transmitted by the bite of ticks infected with the TBE-virus.

New York-based Pfizer's facility in Collegeville handles some of the company's vaccine research. - David Sell